In Vitro and In Vivo Evaluation of Inactivated Rift Valley Fever Virus Vaccine
In Vitro and In Vivo Evaluation of Inactivated Rift Valley Fever Virus Vaccine
Eman, M. M. Soliman*; Taha, M. M.*;El-Sanousi A,;Shalaby M. S. Wasscl , Youscf Adel*
ABSTRACT
In this study, 5 batches of inactivated rift valley fever (RVF) virus vaccine (ZH501) were evaluated according to Office Internationale Epizooties (OIE) RVF evaluation protocol. The tested batches proved to be sterile and safe when inoculated subcutaneously (S/C) and intraperitoneally(I/P) into mice (3-5 days old) and lambs without showing adverse post vaccinal reactions. Duration of immunity to RVF virus in vaccinated sheep has been determined by using both serum neutralization test (SNT) and enzyme-linked immunosorbent assay (ELISA) on sera collected weekly up to 7 weeks post vaccination, where the antibody titer elevated from I st WPV till reach the protective level at 5th WPV. Effective doses in mice has been calculated in mice by inoculation of 5 groups of mice (10 each) with 2 doses of five fold diluted vaccine; inoculated mice have been challenged I/P with virulent RVF virus 103 to 104 mouse I/P lethal dose50(MIPLD50), it was ranged from 0.006 - 0.0007. Using the Rt-PCR to confirm the efficacy of binary ethyleneamine as inactivator to RVF virus used in tested vaccine through applying RTPCR on master seed RVF virus as positive control samples, RVF virus after inactivated with binary ethyleneamine and on the eluted RVF antigen from the tested vaccine, the master seed RVF virus gave positive band at 800bp but the RVF virus after inactivation and eluted antigen from vaccine didn't give any bands.
To share on other social networks, click on any share button. What are these?
July 2008
Vol. 5, Iss. 1
